The U.S. Drug Enforcement Administration this week will formalize its production quotas of drugs and substances utilized for medical, scientific and research purposes, settling in on the previously disclosed allocation of 978 pounds of marijuana.
The DEA’s final 2018 aggregate production quotas (APQ), scheduled to be published Wednesday in the Federal Register, are mostly unchanged from the agency’s proposed quotas released in August.
The APQs are set for highly restrictive substances that are classified as Schedule I and II in the Controlled Substances Act. The quotas are set to meet the estimated needs for medical, research and industrial needs.
The DEA lowered quotas for most substances and notably enacted a 20 percent reduction in opioid painkillers such as oxycodone, morphine and codeine. Quotas also were lowered about 6 percent from those set for 2017 for “marihuana” and